Latest & greatest articles for amlodipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amlodipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amlodipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amlodipine

61. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension

A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension Whitcomb C, Enzmann G, Pershadsingh H A, Johnson R, Ciuryla V, Reisin E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two long-acting dihydropyridine calcium antagonists, amlodipine and nisoldipine extended-release, for the treatment of mild to moderate hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with Stage I

2000 NHS Economic Evaluation Database.

62. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. (Abstract)

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. Previous studies have shown that calcium-channel blockers increase morbidity and mortality in patients with chronic heart failure. We studied the effect of a new calcium-channel blocker, amlodipine, in patients with severe chronic heart failure.We randomly assigned 1153 patients with severe chronic heart failure and ejection fractions of less than (...) 30 percent to double-blind treatment with either placebo (582 patients) or amlodipine (571 patients) for 6 to 33 months, while their usual therapy was continued. The randomization was stratified on the basis of whether patients had ischemic or nonischemic causes of heart failure. The primary end point of the study was death from any cause and hospitalization for major cardiovascular events.Primary end points were reached in 42 percent of the placebo group and 39 percent of the amlodipine group

1996 NEJM Controlled trial quality: predicted high